2.7X Revenue Growth Year-Over-Year at US $24 Million for 9-month Period HERZLIYA, Israel and CALGARY, Alberta , Nov. 20, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three and nine-month periods ended September 30, 2024 .
Financial Highlights.
